The CYP2C9*3 allele¹¹ rs1057910 has a more severe impact on enzyme function than *2. While *2 reduces activity to about 50%, *3 reduces it to approximately 5-15% of normal. This makes *3 the most clinically impactful CYP2C9 variant for warfarin dosing.

The Mechanism

The *3 variant causes an isoleucine-to-leucine substitution at position 359²² Amino acid change: isoleucine to leucine at position 359 (I359L), which is located in the substrate recognition site of the enzyme. This dramatically reduces the enzyme's ability to bind and metabolize its substrates. The residual activity is so low (approximately 5-15% of normal³³ 5-15% of normal
Pharmacogenomics of CYP2C9 review) that *3 is sometimes classified as a no-function allele in clinical guidelines. Unlike *2, the *3 allele is found across multiple ancestry groups, with highest frequencies in South Asian populations (about 11%).

The Warfarin Connection

Patients carrying CYP2C9*3 require substantially lower warfarin doses. A patient who is *1/*3 (heterozygous) typically needs about 30-40% less warfarin than a *1/*1 patient. Those who are *3/*3 (homozygous) or compound heterozygous (*2/*3) may need only a fraction of the typical dose. The risk of over-anticoagulation and bleeding is significantly higher during warfarin initiation in these patients.

Combined CYP2C9 + VKORC1

Warfarin dosing is determined by both CYP2C9 (metabolism) and VKORC1 (drug target sensitivity). The combination of CYP2C9*3 with the VKORC1 -1639A allele⁴⁴ rs9923231 creates the most extreme dosing scenario - these patients may need only 1-2mg of warfarin daily, compared to the typical 5mg starting dose. Pharmacogenomic-guided dosing is especially valuable for these individuals.

Practical Implications

If you carry *3, even in heterozygous form, this is clinically significant information. In the event you ever need warfarin therapy, your CYP2C9 genotype should be communicated to your prescribing physician and included in your medical record. The growing availability of direct oral anticoagulants (DOACs like apixaban and rivaroxaban) that do not require CYP2C9-guided dosing provides alternatives in many clinical scenarios. Note that siponimod (for multiple sclerosis) is contraindicated in CYP2C9*3/*3 individuals⁵⁵ contraindicated in CYP2C9*3/*3 individuals
FDA siponimod label due to extremely elevated plasma levels.

The blood vessels that carry blood from the right heart through the lungs depend on a protein called BMPR2¹¹ BMPR2
Bone Morphogenetic Protein Receptor Type 2 — a cell-surface kinase receptor on pulmonary vascular endothelial and smooth muscle cells that relays anti-proliferative BMP signals into the cell nucleus, restraining abnormal vascular wall growth to suppress abnormal muscle growth in the pulmonary artery walls. When this receptor is absent or defective, the tiny arteries in the lungs slowly narrow and stiffen — a process called pulmonary arterial hypertension (PAH) — forcing the right ventricle to pump against ever-increasing resistance until it fails. The BMPR2 c.961C>T variant (p.Arg321Ter) replaces the codon for arginine at position 321 with a premature stop signal, truncating the protein in the middle of its kinase domain and eliminating it through nonsense-mediated mRNA decay²² nonsense-mediated mRNA decay
NMD — a cellular surveillance mechanism that degrades mRNAs containing premature stop codons before they can be translated into truncated and potentially toxic proteins. Activation of NMD leaves only the intact allele to produce functional BMPR2. (NMD).

BMPR2 pathogenic variants are the most common hereditary cause of PAH, accounting for over 75% of familial PAH cases and approximately 15–25% of apparently sporadic (idiopathic) cases. The R321* stop-gain is classified Pathogenic in ClinVar (RCV000461193), supported by two independent clinical genetics laboratories, with the condition Pulmonary hypertension, primary, 1 (PPH1).

The Mechanism

BMPR2 encodes a transmembrane receptor that, when activated by bone morphogenetic protein (BMP) ligands, phosphorylates intracellular SMAD proteins and restrains the proliferation of pulmonary arterial smooth muscle cells. The Arg321 residue falls within the catalytic kinase domain; truncation at this position destroys the entire kinase module. NMD degrades the mutant transcript, leaving the single intact allele — a state of haploinsufficiency³³ haploinsufficiency
Having only one functional copy of a gene when two copies are normally required for adequate gene product. For BMPR2, one copy produces roughly half the normal receptor density, which is insufficient to maintain normal pulmonary vascular homeostasis in some individuals..

Truncating mutations escape the dominant-negative mechanism⁴⁴ Truncating mutations escape the dominant-negative mechanism
Unlike missense BMPR2 variants that produce a malfolded protein capable of poisoning the normal receptor, NMD-positive truncating mutations leave only haploinsufficiency. This is why truncating BMPR2 mutation carriers develop PAH later (typically after age 36) and with less severe hemodynamics than missense carriers, whose abnormal protein actively disrupts signaling. seen with missense variants. This predicts that R321* carriers, when they do develop disease, tend to present at older ages and with less extreme hemodynamic compromise — though the risk of death or transplantation remains substantially elevated once PAH is established.

The Evidence

Survival impact: The largest available data come from an individual participant data meta-analysis of 1,550 PAH patients⁵⁵ individual participant data meta-analysis of 1,550 PAH patients
Evans JDW et al., Lancet Respir Med, 2016 — pooled data from 8 cohorts; 448 (29%) carried any BMPR2 pathogenic variant; analysis adjusted for age and sex at diagnosis. BMPR2 mutation carriers had a 42% higher hazard of death or lung transplantation (HR 1.42, 95% CI 1.15–1.75) and 27% higher all-cause mortality (HR 1.27) than non-carriers. Carriers presented at a mean age of 35.4 years vs 42.0 years in non-carriers, and showed lower vasodilator responsiveness (3% vs 16%).

Truncating vs missense distinction: Austin et al., Respiratory Research, 2009⁶⁶ Austin et al., Respiratory Research, 2009
Compared hemodynamic profiles, age at diagnosis, and survival in 169 HPAH patients stratified by mutation type; truncating mutations spanned all ages while missense mutations clustered before age 36 — the age-based distinction supports NMD as protective against the most severe early-onset disease showed that carriers of truncating mutations (like R321*) develop PAH later and with milder hemodynamics than missense carriers, consistent with haploinsufficiency rather than dominant negative disruption.

Screening in asymptomatic carriers: The DELPHI-2 study⁷⁷ DELPHI-2 study
Montani D et al., Eur Respir J 2021; 55 asymptomatic adults carrying BMPR2 mutations enrolled prospectively; annual multimodal screening protocol; all detected PAH cases were low-risk at identification followed 55 asymptomatic BMPR2 carriers prospectively. Annual PAH incidence was 2.3% overall — 0.99% per year in males and 3.5% per year in females, consistent with the known sex-dependent penetrance. Cases identified by screening were all at low-risk stage and responded well to oral therapy — demonstrating that surveillance enables early, effective treatment.

Penetrance and sex dimorphism: Lifetime risk of developing PAH with a BMPR2 pathogenic variant is approximately 14% in males and 42% in females. The reason females have higher penetrance is not fully understood but may involve hormonal regulation of pulmonary vascular tone and BMPR2 expression.

Practical Actions

Identifying an R321* carrier before PAH develops is the key clinical opportunity: the DELPHI-2 study demonstrated that screening-detected cases are at low-risk and treatable with oral monotherapy, whereas symptomatic cases typically present with more advanced disease. Annual echocardiographic screening is the minimum standard; right heart catheterization is indicated when screening detects elevated pulmonary pressure estimates or symptoms.

Each first-degree biological relative has a 50% chance of inheriting the R321* variant. Cascade genetic testing identifies relatives who need surveillance before symptoms develop.

Interactions

The companion BMPR2 variant rs1060502576 (also in this batch) tags a distinct mutation in the same gene via the same haploinsufficiency mechanism. Compound heterozygosity for two BMPR2 loss-of-function alleles would be expected to cause more severe or earlier-onset PAH, though documented compound BMPR2 heterozygotes are extremely rare. Other PAH-associated genes — ACVRL1 (ALK1), ENG (endoglin), SMAD9, CAV1, KCNK3 — interact with the same BMP-SMAD signaling pathway and can modify penetrance. Carriers with additional risk factors (female sex, oral contraceptive use, anorexigens, portal hypertension, HIV) have meaningfully higher lifetime risk of clinical PAH expression.

The JAK2 gene encodes Janus Kinase 2, a critical signal transduction enzyme in the JAK-STAT pathway¹¹ JAK-STAT pathway
A signaling cascade where cytokine binding activates Janus kinases, which phosphorylate STAT transcription factors to regulate gene expression controlling immunity, cell growth, and barrier function. The rs10758669 variant sits in an intergenic region near JAK2 on chromosome 9p24 and was first identified as a Crohn's disease susceptibility locus in a landmark GWAS²² first identified as a Crohn's disease susceptibility locus in a landmark GWAS
Barrett et al. identified JAK2 among 21 new CD susceptibility regions in a study of 3,230 cases and 4,829 controls, subsequently confirmed for both Crohn's disease and ulcerative colitis across multiple populations. The C allele increases JAK2 expression in immune cells, amplifying inflammatory signaling and compromising the intestinal barrier that normally prevents bacterial translocation into deeper tissue.

The Mechanism

Unlike coding variants that alter protein structure, rs10758669 is a regulatory variant that influences how much JAK2 protein is produced. Macrophages from CC risk carriers show significantly increased JAK2 mRNA and protein expression compared to AA carriers³³ Macrophages from CC risk carriers show significantly increased JAK2 mRNA and protein expression compared to AA carriers
Hedl & Abraham showed that CC carriers demonstrate increased JAK2 expression and elevated NOD2-induced JAK2 phosphorylation, with CA carriers showing intermediate levels. This gain-of-function effect amplifies JAK-STAT signaling downstream of innate immune receptors like NOD2, shifting the cytokine balance toward pro-inflammatory responses.

The consequences for gut barrier function are direct. The JAK-STAT pathway regulates expression and localization of tight junction proteins that seal the spaces between intestinal epithelial cells. Overactive JAK-STAT signaling upregulates claudin-2⁴⁴ claudin-2
A pore-forming tight junction protein; higher levels increase paracellular permeability to ions and small molecules, which creates channels that increase paracellular permeability. Simultaneously, it reduces expression and mislocates barrier-forming proteins like ZO-1, occludin, and JAM-A, weakening the leak pathway that normally restricts passage of larger molecules. The result is increased intestinal permeability — the measurable functional consequence demonstrated in rs10758669 C allele carriers.

The Evidence

A meta-analysis of 11 studies encompassing 7,009 CD patients, 7,929 UC patients, and 19,235 controls⁵⁵ A meta-analysis of 11 studies encompassing 7,009 CD patients, 7,929 UC patients, and 19,235 controls
Zhang et al. found the C allele was a risk factor for both Crohn's disease and ulcerative colitis, especially in Caucasian populations established the association firmly. For Crohn's disease, CC homozygotes face an OR of 1.29 (95% CI: 1.17-1.43) versus AA, while AC heterozygotes show OR 1.16 (95% CI: 1.08-1.24). For ulcerative colitis, the effects are comparable: CC versus AA OR 1.33 (95% CI: 1.20-1.47), AC versus AA OR 1.14 (95% CI: 1.06-1.22). The association is strongest in Caucasian populations, with no significant effect observed in Asian cohorts.

Prager et al. directly demonstrated the barrier dysfunction mechanism⁶⁶ Prager et al. directly demonstrated the barrier dysfunction mechanism
In 464 CD patients, 292 UC patients, and 508 controls, C allele carriers showed increased intestinal permeability measured by lactulose/mannitol ratio during CD remission (p=0.004). This is significant because permeability was measured during remission, meaning the barrier defect persists independently of active inflammation. The overall OR for CD association was 1.25 (95% CI: 1.04-1.50).

Functional studies revealed the gain-of-function mechanism⁷⁷ Functional studies revealed the gain-of-function mechanism
CC carriers' macrophages demonstrate increased NOD2-induced JAK2 phosphorylation and altered pro-inflammatory cytokine secretion, with autocrine IL-10, IL-4, IL-22, and TSLP cooperatively suppressing pro-inflammatory responses through JAK-dependent feedback loops — loops that become amplified with the C allele.

Practical Implications

The clinical relevance of this variant is twofold: it identifies individuals at increased risk for IBD and, more importantly, it points to intestinal barrier integrity as a targetable mechanism. Unlike variants that affect immune recognition or autophagy, rs10758669 acts through barrier permeability, which can be supported through specific nutritional and lifestyle strategies. L-glutamine is the primary fuel for enterocytes and has been shown to promote tight junction protein expression including ZO-1, claudin-1, and occludin⁸⁸ has been shown to promote tight junction protein expression including ZO-1, claudin-1, and occludin
Glutamine supplementation reversed villus atrophy and restored tight junction protein expression in multiple experimental models. Zinc carnosine stabilizes gut mucosa and has been shown in controlled trials to prevent NSAID-induced permeability increases⁹⁹ has been shown in controlled trials to prevent NSAID-induced permeability increases
A threefold increase in gut permeability from indomethacin was abolished by co-administration of zinc carnosine. Butyrate, a short-chain fatty acid produced by fermenting resistant starch and fiber, tightens epithelial barriers through AMPK-mediated tight junction assembly, facilitating the relocalization of ZO-1 and occludin to cell junctions¹⁰¹⁰ tightens epithelial barriers through AMPK-mediated tight junction assembly, facilitating the relocalization of ZO-1 and occludin to cell junctions.

Importantly, NSAIDs are particularly problematic for carriers of this variant. All conventional NSAIDs increase intestinal permeability within 24 hours of ingestion through mitochondrial uncoupling in enterocytes, compounding the genetically elevated permeability from enhanced JAK-STAT signaling.

The therapeutic context is also noteworthy: JAK inhibitors (tofacitinib, upadacitinib) are now approved for IBD treatment, directly targeting the pathway this variant upregulates. Tofacitinib has been shown to prevent ZO-1 relocalization and reduce claudin-2 expression, essentially reversing the barrier defect at the molecular level.

Interactions

rs10758669 interacts with other IBD susceptibility loci through convergent pathways. NOD2 variants (rs2066844, rs2066845) are particularly relevant because NOD2 signaling directly activates JAK2 phosphorylation — CC carriers with NOD2 risk variants would experience amplified innate immune signaling upon bacterial sensing. ATG16L1 T300A (rs2241880) compounds the risk through a complementary mechanism: impaired autophagy allows bacteria to persist while enhanced JAK-STAT signaling drives excessive inflammatory responses to those bacteria. IRGM (rs13361189) and MST1 (rs3197999) variants further impair bacterial handling and macrophage function, creating a multilayered defect in gut innate immunity when combined with enhanced JAK2 signaling.

Your tonsils are not just an annoyance — they are the front-line training grounds of your immune system, strategically positioned at the gateway between the outside world and your body. Lymphotoxin beta receptor (LTBR)¹¹ Lymphotoxin beta receptor (LTBR)
A member of the TNF receptor superfamily, LTBR binds lymphotoxin-α₁β₂ and LIGHT to activate the non-canonical NF-κB pathway is the master organizer of these structures. Without robust LTBR signaling, the architecture of lymph nodes, Peyer's patches, and tonsillar tissue cannot fully develop or maintain itself — leaving mucosal immune defense poorly organized and less effective. The rs10849448 variant sits in the regulatory 5' UTR region of LTBR, where it likely influences how much receptor protein the gene produces.

The Mechanism

LTBR signaling drives the development and maintenance of secondary lymphoid organs (SLOs) — the lymph nodes, spleen, tonsils, and Peyer's patches that intercept pathogens before they enter the bloodstream. The receptor binds two ligands: lymphotoxin-α₁β₂ (a complex of lymphotoxin-α and lymphotoxin-β produced by lymphocytes) and LIGHT (also called TNFSF14). When these ligands engage LTBR, they activate the non-canonical NF-κB pathway²² non-canonical NF-κB pathway
This alternative NF-κB signaling arm drives the production of homeostatic chemokines (CXCL13, CCL19, CCL21) that organize B and T cell zones inside lymphoid organs, enabling the formation of germinal centers³³ germinal centers
The specialized structures inside lymph nodes where B cells undergo affinity maturation and class-switching to produce high-quality antibodies.

The rs10849448 A>G polymorphism falls in the 5' UTR of LTBR — a region that controls transcript stability and translational efficiency. The risk A allele is associated with altered LTBR expression, which would impair the chemokine gradients needed for proper lymphoid architecture and germinal center reactions. GWAS evidence confirms the biological plausibility: the same locus independently associates with lower CXCL13 levels⁴⁴ CXCL13 levels
CXCL13 is a key B-cell homing chemokine produced in response to LTBR signaling and essential for germinal center formation in plasma, consistent with reduced LTBR pathway activity.

The Evidence

The A allele's role in infection susceptibility was established in a landmark genome-wide association study of 23 common infections⁵⁵ genome-wide association study of 23 common infections
Tian et al. analyzed 200,000+ individuals of European ancestry through 23andMe, examining phenotypes from tonsillectomy to tuberculosis that identified rs10849448 as the strongest non-HLA genome-wide signal for tonsillectomy (OR=1.13, P=2×10⁻³⁵). The same A allele was previously identified in a dense genotyping study of juvenile idiopathic arthritis⁶⁶ dense genotyping study of juvenile idiopathic arthritis
Hinks et al. used the Immunochip array to study 2,816 JIA cases and 13,056 controls showing association with oligoarticular and RF-negative JIA (OR=1.24, P=5×10⁻⁹) — forms of JIA with prominent involvement of mucosal immune dysregulation.

The immune cell quantitative data reinforces the picture from a different angle. A massive blood trait GWAS (Vuckovic et al., Cell 2020⁷⁷ Vuckovic et al., Cell 2020
The Polygenic and Monogenic Basis of Blood Traits — 84 institutions, 746,667 participants) found rs10849448 G allele carriers have systematically higher monocyte counts (β=−0.058, P=1×10⁻¹⁰²) — meaning A allele carriers have lower circulating monocytes, a white blood cell type central to pathogen clearance and lymphoid organ homeostasis. The FinnGen upper respiratory disease GWAS⁸⁸ FinnGen upper respiratory disease GWAS
260,405 participants across 8 upper respiratory disease phenotypes likewise found the G allele protective against upper respiratory illness (OR=0.94, P=8×10⁻¹⁵), while A allele carriers had higher rates of disease.

An incidental but notable finding is the association between the A allele and elevated liver enzyme AST (Chen et al. 2021⁹⁹ Chen et al. 2021
Meta-GWAS of UK Biobank and BioBank Japan liver enzymes), suggesting broader effects on immune-mediated inflammation beyond the respiratory tract.

Practical Actions

For A allele carriers, the primary implication is heightened vulnerability to recurrent upper respiratory and throat infections. The tonsillar tissue — central to the first immune response against inhaled and ingested pathogens — may be less robustly organized, making repeated infection more likely and recovery slower. This is also why AA carriers were historically more likely to undergo tonsillectomy: recurrent tonsillitis severe enough to warrant surgery correlates with this genotype at a population level.

The secondary implication — the JIA association — suggests a broader tendency for mucosal immune dysregulation that can tip into autoimmune reactivity in certain environments. Carriers do not inevitably develop JIA, but the shared genetic architecture between recurrent infections and this autoimmune form highlights that the same LTBR pathway controls the balance between defensive responses and aberrant self-reactivity.

Interactions

LTBR works in concert with other TNF superfamily receptors and their shared ligands. The TNFSF13B gene (encoding BAFF/BLyS) and TNFRSF13B (TACI, the BAFF receptor) are key pathway partners — both regulate B cell survival within the germinal centers that LTBR helps organize. Genetic variation in the TNF/LT locus on chromosome 6p21 (near HLA) also modulates lymphoid architecture, and the tonsillectomy GWAS found multiple independent HLA-region signals alongside rs10849448, suggesting additive risk when LTBR dysregulation combines with HLA-mediated immune recognition changes.

PPARG¹¹ Full name: Peroxisome Proliferator-Activated Receptor Gamma — a nuclear receptor that controls adipocyte differentiation, fatty acid storage, and insulin sensitisation is the master regulator of fat-cell biology. Unlike the well-studied Pro12Ala coding variant (rs1801282), the C-681G variant (rs10865710) sits in the 5' regulatory region of the gene, roughly 681 base-pairs upstream of the transcription start site, in a region that functions as an active transcriptional enhancer²² Enhancers are non-coding DNA elements that bind transcription factors and dramatically amplify nearby gene expression.

The Mechanism

The variant lies within a functional enhancer element that binds the transcription factor CREB2³³ CREB2
CREB2 (also known as ATF4) is a stress-responsive transcription factor that activates gene expression by binding to CRE motifs in enhancer and promoter regions. Luciferase reporter assays demonstrated that the G allele reduces enhancer activity by approximately 29% compared to the reference C allele (0.068 ± 0.004 vs. 0.096 ± 0.002, P = 0.0005). This reduced transcriptional drive results in lower PPARγ protein levels in tissues that depend on the enhancer. Because PPARγ is the primary driver of insulin sensitisation in adipose tissue and the target of thiazolidinedione⁴⁴ Thiazolidinediones (TZDs) such as pioglitazone and rosiglitazone work by binding and activating PPARγ antidiabetic drugs, even a modest suppression of expression has downstream consequences for glucose disposal, lipid handling, and cardiovascular risk.

The Evidence

Lu et al. (2019)⁵⁵ Lu et al. (2019)
Lu H et al. Enhancer polymorphism rs10865710 associated with traumatic sepsis is a regulator of PPARG gene expression. Crit Care, 2019 provided the first mechanistic proof that rs10865710 is a functional regulatory variant — not merely a statistical association. In 797 Han Chinese trauma patients, the G allele was associated with sepsis susceptibility (OR 1.41, 95% CI 1.11–1.79, P = 0.004), replicated in a second cohort (OR 1.45, P = 0.046), and meta-analysed at OR 1.38 (95% CI 1.17–1.71, P < 0.0001). Crucially, genotype correlated directly with measured PPARγ expression levels (P = 9.2 × 10⁻⁵), establishing the regulatory mechanism.

For metabolic disease, Song et al. (2022)⁶⁶ Song et al. (2022)
Song Y et al. rs10865710 polymorphism in PPARG promoter is associated with the severity of type 2 diabetes mellitus and coronary artery disease in a Chinese population. Postgrad Med J, 2022 showed in 635 subjects that G allele carriers with T2DM had significantly elevated glucose, triglycerides, apolipoprotein B, and lipoprotein(a). Among CAD patients, G allele carriers had higher Gensini scores and more diseased coronary vessels, suggesting the variant tracks with metabolic and atherogenic burden.

Cao et al. (2012)⁷⁷ Cao et al. (2012)
Cao CY et al. The C-681G polymorphism of the PPAR-γ gene is associated with susceptibility to non-alcoholic fatty liver disease. Tohoku J Exp Med, 2012 found the G allele was significantly more frequent in NAFLD patients (41.1%) than controls (34.8%, P = 0.03), and a haplotype carrying the G allele increased NAFLD susceptibility.

A Chinese Han case-control study (n = 1,106) by Zhang et al. (2017)⁸⁸ Zhang et al. (2017)
Zhang X et al. Gene-gene interaction between PPARG and CYP1A1 gene on coronary artery disease in the Chinese Han Population. Oncotarget, 2017 reported an OR of 1.47 (95% CI 1.15–1.92) for CAD in homozygous GG carriers.

Practical Implications

The C allele (reference, no-change) predominates globally: ~56% of people are CC, 38% are CG, and 6% are GG. The G allele frequency is fairly uniform across ancestries (22–33%), meaning this variant does not exhibit the strong ancestry-stratification seen in some metabolic SNPs. For G allele carriers the key modifiable factors are those that most directly compensate for reduced PPARγ activity: dietary saturated fat load (which increases the demand on fat-cell storage and lipid clearance), triglyceride levels, and glucose control markers.

Interactions

rs10865710 acts synergistically with the Pro12Ala coding variant (rs1801282) in the same gene. Cecil et al. found opposing and interacting growth phenotypes when both variants were analysed together in children. A five-way gene-gene interaction including rs10865710 and SNPs in PPARD and PPARA was linked to abdominal obesity risk. As a promoter variant, rs10865710 is plausibly additive with rs1801282 — the coding variant changes receptor function while rs10865710 changes receptor abundance. Carriers of G at rs10865710 and CC (Pro/Pro) at rs1801282 combine lower PPARγ levels with a less efficient receptor, compounding metabolic disadvantage.

rs10938397 sits in a regulatory region near GNPDA2 (glucosamine-6-phosphate deaminase 2) on chromosome 4p12 and was identified in the landmark GIANT consortium GWAS¹¹ GIANT consortium GWAS
Willer et al. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nature Genetics, 2009 as one of six new obesity-associated loci, with a per-allele BMI increase of 0.19 kg/m² and a combined p-value of 3.4×10⁻¹⁶ across >90,000 individuals. The G allele is the risk allele. Unlike FTO — which acts through adipocyte thermogenesis — and MC4R and TMEM18 — which act through appetite suppression — GNPDA2 operates through a distinct metabolic channel: the hexosamine signaling pathway²² hexosamine signaling pathway
One of the main nutrient-sensing pathways, directing glucose and amino acid metabolism toward cellular signaling rather than energy storage.

The Mechanism

GNPDA2 encodes an allosteric enzyme that catalyzes the reversible conversion of D-glucosamine-6-phosphate to D-fructose-6-phosphate and ammonium. This reaction sits at a critical junction: it opposes the action of GFAT (glutamine-fructose-6-phosphate amidotransferase³³ glutamine-fructose-6-phosphate amidotransferase
The rate-limiting enzyme feeding into the hexosamine biosynthesis pathway, which produces UDP-GlcNAc for protein O-GlcNAcylation and cellular signaling), functioning as a brake on hexosamine flux. The hexosamine pathway is a nutrient sensor — its output, UDP-GlcNAc, modifies proteins and influences insulin signaling, gene expression, and cellular metabolism in proportion to glucose availability.

GNPDA2 is highly expressed in the hypothalamus⁴⁴ highly expressed in the hypothalamus
Specifically in the arcuate nucleus (ARC), dorsomedial hypothalamus (DMH), lateral hypothalamic area (LHA), and paraventricular nucleus (PVN) and in adipose tissue, with lower expression in muscle and liver. A 2021 functional study⁵⁵ 2021 functional study
Central administration of a GNPDA2 antagonist into the third ventricle of rats; Frontiers in Nutrition, 2021 showed that central GNPDA2 inhibition does not alter food intake or body weight — ruling out appetite as the primary mechanism — but causes glucose intolerance during an intraperitoneal glucose challenge without changing insulin levels. This positions GNPDA2 as a central regulator of glucose handling, with effects mediated through insulin sensitivity rather than insulin secretion or appetite drive.

In adipose tissue, the picture is complementary: a 2019 study⁶⁶ 2019 study
Wu et al. GNPDA2 Gene Affects Adipogenesis and Alters the Transcriptome Profile of Human Adipose-Derived Mesenchymal Stem Cells. International Journal of Endocrinology, 2019 demonstrated that overexpression of GNPDA2 in human adipose-derived mesenchymal stem cells enhances lipid droplet accumulation and adipocyte differentiation, while knockdown suppresses adipogenesis. The transcriptome changes affected genes involved in fatty acid metabolism, lipid modification, and glucose homeostasis.

The Evidence

The association is among the most robustly replicated in obesity genetics. The original GIANT discovery in 32,000 European subjects with replication in 59,000 more⁷⁷ 32,000 European subjects with replication in 59,000 more
Willer et al. Nature Genetics, 2009 was confirmed in a 249,796-individual meta-analysis (Speliotes et al. Nature Genetics, 2010⁸⁸ Speliotes et al. Nature Genetics, 2010) and the largest BMI GWAS to date, 339,224 individuals⁹⁹ 339,224 individuals
Locke et al. Nature, 2015.

In a Danish cohort of 18,014 adults, the G allele was associated with OR 1.15 for obesity (p = 1.1×10⁻⁴)¹⁰¹⁰ OR 1.15 for obesity (p = 1.1×10⁻⁴)
Sandholt et al. Studies of Metabolic Phenotypic Correlates of 15 Obesity Associated Gene Variants. PLOS ONE, 2011, BMI increase of 0.28 kg/m² per allele, and a 0.61 cm increase in waist circumference. Nominal associations with fasting insulin and HOMA-IR¹¹¹¹ HOMA-IR
Homeostatic Model Assessment of Insulin Resistance — a measure of insulin sensitivity derived from fasting glucose and insulin were also observed but did not survive correction for multiple testing.

In Mexican children, the association was stronger: OR 1.30 for obesity (p = 1.34×10⁻³)¹²¹² OR 1.30 for obesity (p = 1.34×10⁻³)
Mejia-Benitez et al. BMC Medical Genetics, 2013. A Chinese study found the G allele associated with increased BMI, fat mass percentage, and waist-to-height ratio in children, with effects varying by sex and pubertal stage. A Chinese Han adult study found the G allele more prevalent in healthy controls than in diabetic groups, suggesting the obesity risk mechanism is distinct from type 2 diabetes susceptibility at this locus.

The G allele frequency is approximately 0.43 in Europeans (risk allele frequency 41% in the Danish cohort) — making this a very common variant. The GG genotype, carrying the highest risk, occurs in ~18% of Europeans.

Practical Implications

Because GNPDA2's CNS role is glucose homeostasis rather than appetite, the primary intervention target for G allele carriers is glucose and insulin metabolism, not eating behavior. G allele carriers should prioritize dietary patterns that reduce glucose spikes and support insulin sensitivity, and monitor fasting glucose and insulin markers periodically to detect early insulin resistance.

In adipose tissue, the pro-adipogenic effect of GNPDA2 suggests that G allele carriers may have a modestly increased tendency to convert energy surplus into fat. Minimizing repeated glycemic surges — which drive hexosamine pathway flux upward — is a specific, mechanism-targeted strategy for this genotype.

Interactions

rs10938397 contributes to a polygenic obesity risk profile alongside FTO (rs9939609), MC4R (rs17782313), TMEM18 (rs6548238), and NEGR1 (rs2815752). Each operates through a distinct mechanism — FTO via thermogenesis, MC4R and TMEM18 via appetite suppression, NEGR1 via hypothalamic circuit development, and GNPDA2 via hexosamine-mediated glucose homeostasis and adipogenesis. GWAS evidence indicates these effects are additive: carrying risk alleles at multiple loci compounds the BMI increase, and a person with risk alleles at GNPDA2 plus FTO or MC4R faces a higher cumulative genetic burden than at either locus alone. No synergistic (multiplicative) interaction has been documented among these loci — their combined effect is the sum of their individual contributions.

Deep sleep depends on the brain's ability to quiet itself. That quieting is controlled by GABAergic neurons¹¹ GABAergic neurons
Inhibitory neurons that release gamma-aminobutyric acid (GABA), the brain's primary inhibitory neurotransmitter, to reduce neural excitability — and the precise assembly of their synapses is governed by a molecular handshake between two proteins: neuroligin-2 (NL2) and neurexin. MDGA1 (MAM Domain Containing Glycosylphosphatidylinositol Anchor 1) acts as a gatekeeper that regulates this handshake, and the rs10947690 Leu61Pro variant shifts the balance in a direction that weakens GABAergic signaling and, in large-scale human genetics studies, reliably increases the risk of chronic insomnia.

The Mechanism

Inhibitory synapses form when neuroligin-2 (on the postsynaptic membrane) binds to neurexin²² neurexin
A presynaptic adhesion protein that anchors the synapse and recruits the GABA release machinery on the sending neuron on the presynaptic side. MDGA1 binds NL2 through three contact interfaces and physically blocks the neurexin-binding site, preventing the trans-synaptic adhesion required for inhibitory synapse formation.

The 2017 crystal structure study³³ 2017 crystal structure study
Kim JA et al. Structural Insights into Modulation of Neurexin-Neuroligin Trans-synaptic Adhesion by MDGA1/Neuroligin-2 Complex. Neuron, 2017 showed that all three MDGA1-NL2 contact points are required for full suppression of synaptogenic activity, and that MDGA1 selectively targets NL2 (the inhibitory-synapse neuroligin) rather than NL1 (the excitatory-synapse neuroligin). This selectivity means MDGA1 is a dedicated brake on inhibitory circuit assembly.

The Leu61Pro substitution falls in the immunoglobulin domain 1 (Ig1) of MDGA1, one of the three contact interfaces. Proline introduces a rigid kink in the protein backbone that destabilizes the Ig1 fold. A structurally perturbed Ig1 domain has reduced affinity for NL2 — meaning the MDGA1 brake becomes hyperactive, or alternatively, the protein adopts an aberrant conformation that interferes with normal NL2 trafficking. Either outcome reduces functional inhibitory synapse density.

A 2025 study in the lateral habenula⁴⁴ 2025 study in the lateral habenula
Wang et al. Chronic stress induces depression through MDGA1-Neuroligin2 mediated suppression of inhibitory synapses in the lateral habenula. Theranostics, 2025 showed that elevated MDGA1-Nlgn2 interaction suppresses GABAergic synapse density; blocking this interaction increased inhibitory transmission and conferred resistance to stress-induced depressive behavior. This convergent evidence supports the model that rs10947690-G, by disrupting normal MDGA1 structure, perturbs the inhibitory synapse set-point in brain circuits regulating sleep and arousal.

The Evidence

The strongest evidence comes from two landmark 2019 GWAS studies published simultaneously in Nature Genetics.

Jansen et al. (2019)⁵⁵ Jansen et al. (2019)
Jansen PR et al. Genome-wide analysis of insomnia in 1,331,010 individuals identifies new risk loci and functional pathways. Nature Genetics, 2019 — the largest insomnia GWAS to date — identified rs10947690-G as a genome-wide significant insomnia locus (OR 1.048, p = 4×10⁻¹²), with a sex-stratified female analysis also reaching significance (OR 1.049, p = 2×10⁻⁸). The 202 loci identified explained 2.6% of the variance in insomnia, with enrichment in striatal, hypothalamic, and claustrum neurons — all regions involved in sleep-wake regulation.

Lane et al. (2019)⁶⁶ Lane et al. (2019)
Lane JM et al. Biological and clinical insights from genetics of insomnia symptoms. Nature Genetics, 2019 independently identified 57 insomnia loci across 453,379 UK Biobank participants and validation cohorts totaling over 160,000 additional individuals. Both studies found enrichment in ubiquitin-mediated proteolysis pathways and multiple brain region expression signatures consistent with the synaptic regulation hypothesis.

Watanabe et al. (2022)⁷⁷ Watanabe et al. (2022)
Watanabe K et al. Genome-wide meta-analysis of insomnia prioritizes genes associated with metabolic and psychiatric pathways. Nature Genetics, 2022 extended the analysis to 2.4 million individuals, identifying 554 risk loci. Gene prioritization among 3,898 candidates highlighted synaptic signaling and neuronal differentiation as the primary functional pathways — consistent with MDGA1's role.

Hatcher et al. (2019)⁸⁸ Hatcher et al. (2019)
Hatcher C et al. Leveraging brain cortex-derived molecular data to elucidate epigenetic and transcriptomic drivers of complex traits and disease. Translational Psychiatry, 2019 used Bayesian colocalization of prefrontal cortex gene expression, DNA methylation, and histone acetylation data with GWAS summary statistics, identifying MDGA1 as a novel locus where the same genetic variant influences both brain gene expression and insomnia susceptibility — strengthening the case for a functional, brain-expressed mechanism.

Practical Actions

GABAergic signaling tone can be supported through several nutritional strategies. Magnesium acts as an NMDA receptor antagonist and GABA modulator⁹⁹ NMDA receptor antagonist and GABA modulator
Magnesium blocks NMDA (excitatory glutamate) receptors and potentiates GABA-A receptor activity, effectively supporting inhibitory tone and has demonstrated sleep improvements in controlled trials — specifically increasing slow-wave sleep and reducing nocturnal cortisol. Glycine, at 3 g before bed, activates NMDA receptors in the suprachiasmatic nucleus to promote sleep onset and has shown reductions in sleep fragmentation in human trials. Taurine potentiates GABA-A and GABA-B receptors and modulates inhibitory tone.

For rs10947690-G carriers, these interventions address the downstream consequence of reduced inhibitory synapse density: insufficient GABAergic tone at the point of sleep onset.

Interactions

MDGA1's role in GABAergic signaling connects it functionally to other sleep-related pathways. GABAergic tone interacts with cortisol rhythms (HPA axis variants like FKBP5, CRHR1) and with circadian regulation (CLOCK, CRY1, PER3 variants). Individuals carrying both MDGA1 Leu61Pro and circadian variants such as rs1801260 (CLOCK) or rs57875989 (CRY1) may experience compounding insomnia susceptibility from two independent pathways — reduced inhibitory synapse density from MDGA1 and disrupted circadian timing from clock gene variants. No published compound genotype data exist, but the pathway logic is robust.

Every time a joint sustains injury or mechanical stress, a lipid signal called lysophosphatidic acid (LPA)¹¹ lysophosphatidic acid (LPA)
a bioactive phospholipid produced by the enzyme autotaxin (ATX), which converts lysophosphatidylcholine into LPA in the synovial fluid floods the damaged tissue. LPA binds to a family of receptors embedded in the surface of cartilage cells, synovial fibroblasts, and bone stromal cells. The first and most prevalent of these receptors is LPAR1 — encoded by the LPAR1 gene (formerly known as EDG2, for endothelial differentiation gene 2). Rs10980705 sits in the upstream regulatory region of LPAR1, roughly 2 kilobases before the transcription start site. The T allele at this position drives higher LPAR1 gene expression in synovial tissue, amplifying the cellular response to LPA in the joint microenvironment.

The Mechanism

The LPA–LPAR1 signaling axis is a key regulator of how joint tissue responds to damage. In healthy cartilage, autotaxin expression is negligible²² autotaxin expression is negligible
intact articular cartilage expresses minimal ATX; it is upregulated only after injury when stromal cells migrate to the damage site. After injury, rising LPA concentrations activate LPAR1 on chondrocytes and stromal cells, triggering MAP kinase (p38 MAPK) and PI3 kinase (Akt) signaling cascades that increase collagen type I gene expression. Collagen I is the structural hallmark of fibrocartilage — the inferior scar tissue that replaces lost hyaline cartilage. Elevated LPAR1 activity therefore shifts the tissue repair balance toward fibrous healing rather than the collagen II–rich hyaline cartilage the joint needs.

In synovial fibroblasts, LPAR1 also promotes cell survival and proliferation in response to the inflammatory cytokine TNF-alpha. A 2012 study³³ A 2012 study
Orosa et al., Arthritis & Rheumatism 2012 found LPAR1 expression was elevated in rheumatoid arthritis fibroblast-like synoviocytes compared to osteoarthritis cells, and that suppressing LPAR1 shifted TNF-stimulated cells away from proliferation and toward apoptosis. The implication: higher LPAR1 expression in the joint promotes synoviocyte survival and persistence, contributing to the pannus-like tissue that characterizes chronic arthritic conditions.

Intra-articular LPA itself is directly destructive. A 2022 rat model⁴⁴ A 2022 rat model
McDougall & Reid, Frontiers in Immunology 2022 showed that a single intra-articular LPA injection produced proteoglycan loss, focal bone erosion, and synovitis within 28 days, with 20–30% reductions in mechanical pain thresholds. The T allele of rs10980705 amplifies sensitivity to exactly this signal by driving higher receptor expression in synovial tissue.

The Evidence

The original genetic association was identified by Mototani et al. in 2008⁵⁵ Mototani et al. in 2008
Mototani H et al., Human Molecular Genetics 2008. In two independent Japanese populations, the T allele of rs10980705 was significantly associated with knee osteoarthritis, with the T allele conferring increased susceptibility. Crucially, the team performed functional luciferase reporter assays in synovial cells and demonstrated that the T allele showed significantly higher transcriptional activity than the C allele — establishing a mechanistic link, not just a statistical signal. This places LPAR1 in the same category as a handful of arthritis-associated genes with documented functional variants, not merely statistical associations.

Attempted replication in European and Chinese cohorts produced mixed results. Dieguez-Gonzalez et al. in 2009⁶⁶ Dieguez-Gonzalez et al. in 2009
Annals of the Rheumatic Diseases 2009 tested rs10980705 in five sample collections and found no statistically significant association in any individual cohort. However, a meta-analysis combining all collections — including the original Japanese data — did yield a modest but statistically significant result. The most likely explanation: the T allele frequency in African populations is notably low (about 5%), while European and East Asian frequencies are similar (~23–25%), so the original Japanese association may reflect a real but modest effect that requires larger sample sizes to replicate in European populations. Population-specific genetic architecture, linkage disequilibrium patterns, and differential environmental exposures may also modulate the effect.

Corroborating the LPA pathway's biological relevance, ATX inhibitor studies⁷⁷ ATX inhibitor studies
Datta et al., Osteoarthritis and Cartilage Open 2020 show that blocking upstream LPA production partially protects knee cartilage from degeneration in surgical osteoarthritis mouse models, suggesting therapeutic relevance of the pathway beyond genetics alone.

Practical Actions

Carrying one or two T alleles at rs10980705 does not guarantee osteoarthritis. This is an emerging-evidence association, strongest in Japanese populations. However, the functional data are compelling: if you carry the T allele, your LPAR1 gene expression in synovial tissue is upregulated, and your joints may be more reactive to the LPA signals released during mechanical stress or injury. This has concrete implications for joint load management, recovery, and monitoring.

The joint most studied in connection with this variant is the knee. Strategies that reduce the cumulative LPA-driven inflammatory burden — such as managing acute joint loads, supporting cartilage matrix quality, and monitoring early joint symptoms — are directly relevant to the biology of this variant.

Interactions

LPAR1 operates within the broader autotaxin–LPA signaling network. ATX (encoded by ENPP2) is the primary enzyme producing LPA in synovial fluid; genetic variants in ENPP2 that influence ATX activity could compound the effect of elevated LPAR1 expression in T-allele carriers. LPAR1 also signals through the same Gi/o and PI3K pathways activated by inflammatory cytokines such as IL-6 (rs1800795) and TNF-related genes, meaning carriers of pro-inflammatory variants in IL6 alongside the LPAR1 T allele may experience amplified synovial inflammation. These interactions are biologically plausible but have not been directly studied in published genetic cohorts for this SNP.

Follicle-stimulating hormone (FSH) is the master regulator of follicle development in women and spermatogenesis in men. It is produced by the pituitary gland when the beta-subunit gene FSHB¹¹ beta-subunit gene FSHB
Located on chromosome 11p14.1, encoding the hormone-specific subunit that confers biological activity is transcribed and translated. rs11031006 is a G-to-A variant located approximately 26 kilobases upstream of the FSHB transcription start site, sitting within a conserved regulatory enhancer rather than the coding sequence of FSHB itself. This locus has emerged as one of the most robustly replicated genetic determinants of circulating FSH levels, female reproductive timing, dizygotic twinning propensity, and PCOS susceptibility — and it also influences male spermatogenic function through its effect on FSH production.

Note on variant identity: rs11031006 is a GWAS lead SNP at the FSHB locus; it is distinct from rs10835638, the -211G>T proximal promoter variant studied in many clinical male infertility trials. Both variants affect FSHB regulation, but through different mechanisms and at different distances from the gene. The two are not in strong linkage disequilibrium. Studies of male infertility citing "FSHB c.-211G>T" refer to rs10835638, while studies citing the 11p14.1 GWAS locus and twinning associations predominantly discuss rs11031006.

The Mechanism

The rs11031006 variant sits within a ~450 base-pair region that is highly conserved across placental mammals, a hallmark of functional regulatory elements. In vitro luciferase assays demonstrate that this region acts as a transcriptional enhancer of FSHB²² In vitro luciferase assays demonstrate that this region acts as a transcriptional enhancer of FSHB
The enhancer augments activin- and GnRH-stimulated FSHB transcription in gonadotrope cell models. The minor A allele creates a stronger binding site for Steroidogenic Factor 1 (SF1)³³ Steroidogenic Factor 1 (SF1)
A nuclear receptor transcription factor essential for gonadotrope cell identity and FSH gene expression, increasing enhancer activity approximately 1.5-fold compared to the major G allele in cell culture experiments.

This in vitro finding presents a mechanistic paradox: the A allele increases FSHB transcription experimentally, yet population data consistently show that individuals carrying the A allele have lower circulating FSH levels, higher LH/FSH ratios, and altered reproductive phenotypes compared to G-allele carriers. The discrepancy likely reflects the complexity of pituitary negative feedback regulation in vivo — the G allele may be associated with higher FSH in part because its carriers have faster hypothalamic-pituitary-gonadal axis dynamics overall. Mouse models partially reconcile this: female mice homozygous for the A-equivalent mutation show fewer litters and abnormal estrous cycling⁴⁴ fewer litters and abnormal estrous cycling
Despite no reduction in baseline FSH measured in the deletion model, the point mutation itself disrupts reproductive cycling, suggesting the locus affects reproductive cycling through mechanisms beyond steady-state FSH levels.

The Evidence

The most robust evidence comes from multiple GWAS. A 2016 study of mothers of spontaneous dizygotic twins (n~95,000 births in Iceland plus replication cohorts)⁵⁵ A 2016 study of mothers of spontaneous dizygotic twins (n~95,000 births in Iceland plus replication cohorts)
Mbarek et al., American Journal of Human Genetics identified rs11031006-G as a genome-wide significant twinning variant (p=1.54×10⁻⁹), with each copy of the G allele increasing the likelihood of a mother delivering fraternal twins by approximately 18% (OR 1.18 per copy). The same G allele was associated with higher serum FSH levels, earlier age at menarche, earlier age at first child, higher lifetime parity, lower PCOS risk, and earlier age at natural menopause — a constellation that collectively points to a more "fast-cycling" reproductive phenotype.

In polycystic ovary syndrome genetics, the 11p14.1 locus containing rs11031006 was identified in European PCOS GWAS as associated with altered LH levels and LH/FSH ratio. Women carrying copies of the A allele show higher LH/FSH ratios⁶⁶ Women carrying copies of the A allele show higher LH/FSH ratios
Consistent with the gonadotropin imbalance characteristic of PCOS, a pattern distinct from G-allele carriers who tend to have higher FSH relative to LH.

The male fertility significance was established in a 2022 GWAS of 760 idiopathic infertile men (validated in 1,140)⁷⁷ 2022 GWAS of 760 idiopathic infertile men (validated in 1,140)
Schubert et al., Journal of Clinical Endocrinology & Metabolism. The 11p14.1 locus (represented by rs11031005, in high LD with rs11031006) was the top genome-wide significant hit for serum FSH levels, explaining 4.65% of FSH variance overall and 6.95% of variance in the oligozoospermic subgroup specifically — a larger effect than the well-studied proximal promoter variant rs10835638 (which explains ~3.6% of FSH variance). Lower FSH in men impairs Sertoli cell function and reduces sperm production; the FSHB locus was identified as a potential etiologic factor in approximately 28% of men with idiopathic infertility.

Practical Implications

The practical implications of this variant differ by sex. In women, the A allele (associated with lower FSH and higher LH/FSH ratio) may contribute to longer menstrual cycles, slightly delayed folliculogenesis, and a reproductive axis phenotype that overlaps with some PCOS features — although rs11031006 alone is not diagnostic of PCOS. Women carrying the AA genotype (approximately 2% of European-ancestry individuals) may wish to discuss FSH and LH panel interpretation with a reproductive endocrinologist if experiencing irregular cycles, delayed conception, or unexplained subfertility.

In men, the A allele is associated with measurably lower FSH levels at the population level, which may impair spermatogenesis. Men with low-normal FSH and idiopathic infertility who carry variants at this locus represent a distinct etiologic subgroup⁸⁸ Men with low-normal FSH and idiopathic infertility who carry variants at this locus represent a distinct etiologic subgroup
Defined as functional secondary hypogonadism with isolated FSH deficiency, this group responds to exogenous FSH treatment with improved sperm parameters. Semen analysis combined with FSH measurement is the key initial investigation for male carriers, particularly for the AA homozygous genotype.

Interactions

rs10835638 (FSHB -211G>T, proximal promoter): This is a separate variant located 211 bp upstream of the FSHB mRNA transcription start site. Both rs11031006 and rs10835638 affect FSHB expression but at different positions and through distinct mechanisms. In men, rs10835638 T allele has been extensively studied and reduces FSH by ~0.51 IU/L per allele and testicular volume by ~3.2 ml. These two variants are not in strong LD and may have partially independent effects; their combined impact on FSH levels in men with idiopathic infertility is additive and warrants separate genotyping.

rs6166 (FSHR N680S): The FSH receptor sensitivity variant interacts functionally with FSHB variants. In men, the effect of FSHB locus variants on FSH-driven spermatogenesis is modulated by FSHR genotype — men with lower FSH production (FSHB A allele) and reduced FSH receptor sensitivity (FSHR GG) have a compounded spermatogenic disadvantage. This interaction has been documented for the proximal FSHB variant, and the same pathway logic applies to rs11031006. A compound action may be warranted when both unfavorable genotypes co-occur.

RORA (RAR-related Orphan Receptor Alpha) occupies a dual role in human biology: it is a core activator of the circadian clock¹¹ circadian clock
RORA binds ROR-response elements in the BMAL1 promoter, driving its transcription and sustaining the ~24-hour oscillation in the suprachiasmatic nucleus and a key regulator of immune tolerance in the airways. The rs11071559 variant sits in the first intron of the RORA-1 transcript on chromosome 15q22.2 — a regulatory region, not a coding sequence — which means it likely influences how much RORA protein is produced rather than altering the protein itself. The best-replicated association for this specific variant is with asthma susceptibility: the common C allele carries slightly elevated risk, while the rarer T allele is protective.

The Mechanism

As an intronic variant with no known amino acid change, rs11071559 is thought to act as a regulatory tag SNP²² regulatory tag SNP
A tag SNP marks a block of correlated variants; rs11071559 may be in linkage disequilibrium with a causal variant that alters a transcription factor binding site or splicing regulatory element in RORA intron 1. RORA itself regulates the promoter activity of NPSR1 (neuropeptide S receptor 1), a gene independently associated with asthma and panic disorder. When RORA expression is altered, NPSR1 promoter activity changes reciprocally³³ NPSR1 promoter activity changes reciprocally
Overexpression of RORA in cell models decreased NPSR1 promoter activity, suggesting a negative regulatory loop. NPSR1 signaling in turn activates a pathway that includes circadian clock genes, creating a feedback loop linking the circadian system to airway inflammation. This may partly explain why asthma symptoms — particularly nocturnal asthma — follow a circadian pattern⁴⁴ circadian pattern
Airway inflammation and bronchoconstriction peak between 2–4 AM in susceptible individuals, mirroring diurnal rhythms in cortisol, melatonin, and mast cell activity.

The Evidence

The asthma association for rs11071559 is among the better-replicated findings in the RORA locus. The APCAT consortium meta-analysis⁵⁵ APCAT consortium meta-analysis
Ramasamy et al. PLOS One 2012 brought this variant to genome-wide significance (p = 2.4 × 10⁻⁹) across six European population-based cohorts totaling approximately 5,751 asthmatics and 28,139 controls. Within the BAMSE and PARSIFAL cohorts, Acevedo et al. 2013⁶⁶ Acevedo et al. 2013
PLOS One found the T allele protective against physician-diagnosed childhood asthma with an odds ratio of 0.71 (95% CI: 0.55–0.92, p = 0.007) in the combined dataset, a modest but replicable effect. Importantly, the RORA association was primarily with asthma diagnosis rather than atopic traits (IgE levels, eczema), suggesting RORA's role in airway inflammation specifically rather than general atopic tendency.

A note on sleep and hormonal phenotypes: RORA is a validated circadian clock gene and BMAL1 activator, and other RORA variants (notably rs75981965) have been associated with sleep duration in a Taiwanese biobank study⁷⁷ Taiwanese biobank study
10,112 subjects, p = 9.93 × 10⁻⁵ after Bonferroni correction. However, rs11071559 itself has not been associated with sleep duration, chronotype, or hormonal traits in any published GWAS. The association for this specific SNP is asthma only. The batch placed this variant in the hormones-sleep category because RORA is a circadian gene, but the actionable evidence for rs11071559 is in airway immunity. Users with the CC genotype should focus on the respiratory health implications described below.

Practical Actions

For the common C-allele carriers (CC or CT), the slightly elevated asthma risk from the RORA locus is modest and modifiable. The circadian-immune link means that circadian disruption amplifies airway inflammation⁸⁸ circadian disruption amplifies airway inflammation
Shift workers and those with social jet lag have higher rates of asthma exacerbation and more severe symptom patterns. Maintaining consistent sleep-wake timing is therefore a genotype-relevant action — not as a generic sleep hygiene recommendation, but because circadian misalignment specifically impairs RORA function in airway epithelial and immune cells, which is the pathway through which this variant acts. Avoiding known asthma triggers and monitoring for nocturnal symptoms are warranted.

Interactions

RORA interacts genetically and biologically with NPSR1 (neuropeptide S receptor 1 gene, chromosome 7p15). The interaction is strongest for nocturnal asthma: rs7164773 in RORA and NPSR1 variants jointly predict asthma phenotype better than either alone. If you have both RORA and NPSR1 risk genotypes and experience primarily night-time or early-morning asthma symptoms, the RORA-NPSR1 interaction may be the relevant mechanism.

The circadian clock gene REV-ERBα (NR1D1) is RORA's functional antagonist at the BMAL1 promoter — both bind the same response element, with opposing effects. Variants in NR1D1 that reduce its repressive activity can partially compensate for reduced RORA activity, and vice versa. Pathway-level interactions between RORA, NR1D1, and RORB on sleep and circadian phenotypes have been reported but not yet linked to this specific rsid.